AIM: The effect of insulin pump [continuous subcutaneous insulin infusion (CSII)] treatment on @entity2412 in a modern clinical setting is largely unknown. We investigated the effect of 4  years CSII treatment on HbA1c, @entity633 and kidney function compared with @entity2794 ( @entity2794 ) in a single-centre clinical setting. METHODS: All @entity1 initiating CSII treatment from 2004 to 2010 and followed for at least 4  years were included in the study: 193 @entity1 with Type  1 @entity6 were matched (1  :  2) with 386 @entity1 treated with @entity2794 in the same period. Matching was based on @entity6 duration, gender, @entity4051 c and normo-, micro- or macroalbuminuria at baseline. Urinary albumin/ @entity1011 ratio (UACR) was measured yearly and annual change assessed from linear regression. RESULTS: CSII- vs. @entity2794 -treated @entity1 were comparable at baseline. After 4  years, HbA1c was 62      11 vs. 68      11  mmol/mol (7.8      1.0 vs. 8.4      1.0 %) (P  <  0.001). Annual UACR change in CSII- vs. @entity2794 -treated @entity1 was [mean (95% confidence interval)] -10.1 (-13.3; -6.8) vs. -1.2 (-3.6; 0.9)% (P  <  0.001). Reduction in UACR was significantly associated with CSII treatment after adjustment for age, gender, @entity6 duration, estimated GFR, UACR, mean arterial pressure, HbA1c , @entity165 , renin-angiotensin- @entity1369 system inhibition, anti- @entity101 treatment and smoking (P  <  0.001). This remained significant (P  <  0.001) when only including @entity1 on stable renin-angiotensin- @entity1369 system inhibition during follow-up (n  =  465). CONCLUSIONS: Treatment with CSII over 4  years independently reduced HbA1c and UACR compared with @entity2794 . Reduced UACR may be due to less glycaemic variability because the effect of CSII on HbA1c could only partially explain the effect. This needs confirmation in randomized controlled trials. This article is protected by copyright. All rights reserved.

Effect of 4  years subcutaneous insulin infusion treatment on XXXX , kidney function and HbA1c compared with @entity2794 : a longitudinal follow-up study.

@entity1 :: ('9606', 'Species') :: ['patients', 'people'] @entity4051 :: ('3039', 'Gene') :: ['HbA1'] @entity1369 :: ('MESH:D000450', 'Chemical') :: ['aldosterone'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity633 :: ('MESH:D000419', 'Disease') :: ['albuminuria'] @entity2794 :: ('MESH:D020773', 'Disease') :: ['MDI', 'multiple daily injections'] @entity2412 :: ('MESH:D048909', 'Disease') :: ['diabetes complications'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity633 :: (MESH:D000419,Disease) :: ['albuminuria']
